The global market for Drug-Coated Balloon Catheters was estimated at US$1.5 Billion in 2024 and is projected to reach US$2.1 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Drug-Coated Balloon Catheters market.
Segments: Type (Paclitaxel, Sirolimus); Product (Coronary Artery Disease, Peripheral Vascular Disease); End-Use (Hospital, Clinics, Ambulatory Surgery Centers)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global 'Drug-Coated Balloon Catheter' Market - Key Trends & Drivers Summarized
Why Are Drug-Coated Balloon Catheters Gaining Traction in Cardiovascular Care?
Drug-coated balloon (DCB) catheters have become a game-changer in interventional cardiology and vascular surgery. Unlike traditional stents, DCBs deliver antiproliferative drugs directly to vessel walls, reducing the risk of restenosis without leaving a permanent implant. These devices are particularly useful for coronary artery disease, peripheral artery disease (PAD), and in-stent restenosis, offering a safer alternative with fewer complications.
What Technological Advances Are Improving DCB Performance?
Breakthroughs in polymer-free drug coatings, hydrophilic delivery systems, and biodegradable carriers have enhanced drug retention and absorption in target arteries. The development of paclitaxel-based and sirolimus-coated DCBs has led to longer-lasting therapeutic effects with minimal side effects. Advances in catheter flexibility, precision drug dosing, and imaging-guided deployment have further improved procedural outcomes.
How Are Regulations and Market Demand Influencing Adoption?
Regulatory bodies like the FDA and CE Marking agencies are increasingly approving DCBs for new indications beyond cardiovascular interventions, expanding their use in diabetic vascular complications and arteriovenous fistula treatments. The rise in minimally invasive surgeries and outpatient procedures has also driven demand for DCBs as a cost-effective and efficient alternative to drug-eluting stents (DES).
What Is Propelling the Market Growth?
The growth in the Drug-Coated Balloon Catheter market is fueled by the rising prevalence of cardiovascular diseases, increasing preference for non-stent-based interventions, and advancements in drug delivery coatings. The aging population, growing adoption of outpatient angioplasty procedures, and ongoing clinical trials for new drug formulations are also key market drivers. Furthermore, the expansion of DCB applications into non-cardiac vascular treatments is broadening their clinical relevance and commercial potential.
Report Scope
The report analyzes the Drug-Coated Balloon Catheters market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Type (Paclitaxel, Sirolimus); Product (Coronary Artery Disease, Peripheral Vascular Disease); End-Use (Hospital, Clinics, Ambulatory Surgery Centers)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Paclitaxel segment, which is expected to reach US$1.3 Billion by 2030 with a CAGR of a 4.9%. The Sirolimus segment is also set to grow at 8.0% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $395.8 Million in 2024, and China, forecasted to grow at an impressive 9.2% CAGR to reach $414.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Drug-Coated Balloon Catheters Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Drug-Coated Balloon Catheters Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Drug-Coated Balloon Catheters Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, Alvimedica, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 48 Featured):
- Abbott Laboratories
- Alvimedica
- B. Braun Melsungen AG
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- BD (Becton, Dickinson and Company)
- Cardionovum GmbH
- Concept Medical Inc.
- Eurocor GmbH
- iVascular S.L.U.
- Koninklijke Philips N.V.
- Lepu Medical Technology Co., Ltd.
- Medtronic plc
- Merit Medical Systems, Inc.
- OrbusNeich Medical Group
- QT Vascular Ltd.
- Shockwave Medical, Inc.
- Surmodics, Inc.
- Terumo Corporation
- TriReme Medical, LLC
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Alvimedica
- B. Braun Melsungen AG
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- BD (Becton, Dickinson and Company)
- Cardionovum GmbH
- Concept Medical Inc.
- Eurocor GmbH
- iVascular S.L.U.
- Koninklijke Philips N.V.
- Lepu Medical Technology Co., Ltd.
- Medtronic plc
- Merit Medical Systems, Inc.
- OrbusNeich Medical Group
- QT Vascular Ltd.
- Shockwave Medical, Inc.
- Surmodics, Inc.
- Terumo Corporation
- TriReme Medical, LLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 375 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 1.5 Billion |
Forecasted Market Value ( USD | $ 2.1 Billion |
Compound Annual Growth Rate | 6.0% |
Regions Covered | Global |